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Introduction: Selective decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination
(SOD) have been shown to improve intensive care unit (ICU) patients’ outcomes. The aim of this study was to
determine the effects of long-term use of SDD and SOD on colistin and tobramycin resistance among gram-negative
bacteria.
Methods: We performed a post hoc analysis of two consecutive multicentre cluster-randomised trials with crossover of
interventions. SDD and SOD were alternately but continuously used during 7 years in five Dutch ICUs participating in
two consecutive cluster-randomised trials. In both trials, to measure colistin and tobramycin resistance among
gram-negative bacteria, rectal and respiratory samples were obtained monthly from all patients present in the ICU.
Results: The prevalence of tobramycin resistance in respiratory and rectal samples decreased significantly during
long-term use of SOD and SDD. (rectal samples risk ratio (RR) 0.35 (0.23 to 0.53); respiratory samples RR 0.48 (0.32 to
0.73), SDD compared to standard care). Colistin resistance in rectal and respiratory samples did not change (rectal
samples RR 0.63 (0.29 to 1.38); respiratory samples RR 1.26 (0.35 to 4.57), SDD compared to standard care).
Conclusions: In this study, in a setting with low antimicrobial resistance rates, the prevalence of resistance against
colistin and tobramycin among gram-negative isolates did not increase during a mean of 7 years of SDD or SOD use.Introduction
Selective digestive tract decontamination (SDD) and se-
lective oropharyngeal decontamination (SOD) aim to
eradicate potential pathogenic microorganisms from the
digestive tract to prevent infections in intensive care pa-
tients. The most commonly used SDD regimen consists
of a non-absorbable antimicrobial mouth paste and gas-
troenteral suspension containing colistin, tobramycin
and amphotericin. In addition, systemic broad-spectrum
antibiotics are administered during the first four days in
the intensive care unit (ICU). SOD consists of the
mouth paste only. Both strategies have been associated
with lower mortality, shortened length of stay in hospital
and ICU, and less ICU-acquired infections such as
bacteremia [1-3]. Routine use of SDD and SOD has
remained controversial, mainly because of the fear that* Correspondence: B.H.J.Wittekamp@umcutrecht.nl
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unless otherwise stated.(long-term) use will increase antibiotic resistance [4,5].
A recent systematic review and meta-analysis failed to
demonstrate such an association, but also concluded
that more evidence is needed regarding the long-term
effects of SDD/SOD on ICU ecology [5]. We, therefore,
measured the prevalence of colistin and tobramycin re-
sistance in five ICUs that have continuously been using
SDD or SOD for 6 years or longer.
Methods
The effects of SOD and SDD were evaluated in a cluster-
randomised cross-over study between 2004 and 2006
(study I). Each of 13 participating ICUs used SDD, SOD
and standard care (no SDD/SOD), as unit-wide measures
for 6 months, with the order of the three periods rando-
mised per ICU. Methodological details and results of the
study have been published previously [3]. A second
cluster-randomised cross-over study (study II) evaluated
the effects of SOD and SDD (without standard care
period) when applied as unit-wide interventions duringtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Five ICUs participated in both studies, and continued to
use SDD as standard care in the interval between studies
(2006 to 2009). These ICUs were contacted to verify that
no changes in infection control strategies had taken place
for the duration of both studies. For both studies, the need
for informed consent was waived by the institutional re-
view board. (See Acknowledgements for full details)
During both studies, monthly point prevalence surveys
were performed, in which rectal swabs and throat swabs
or endotracheal aspirates (respiratory samples) were ob-
tained from all patients present in the ICU on the day of
the survey. This included patients who did not receive
SDD or SOD at the time of the point prevalence survey.
Where possible endotracheal aspirates were obtained,
with throat swabs regarded as the best option in non-
intubated patients.
Microbiology methods
Samples were plated on selective agar, including media
containing polymyxin and tobramycin in local micro-
biology laboratories. Screening for colistin resistance was
done using plates containing polymyxin B (5 mg/l) in
study period I and polymyxin E (4 mg/l) in study period
II. Cultures were analysed semi-quantitatively for growth
of gram-negative bacteria. Minimum inhibitory concentra-
tion (MIC) values for colistin and tobramycin were deter-
mined using automated testing. EUCAST cutoff values
were used to determine antibiotic resistance to colistin
and tobramycin. Bacteria with susceptibility reported as
intermediate (I) or resistant (R) were considered resistant.
Species with intrinsic resistance to colistin, such as Mor-
ganella, Citrobacter and Serratia spp. were excluded from
the analysis for colistin resistance. Additional information
on the characteristics of the two studies, including micro-
biology methods used can be found in Additional file 1.Figure 1 Time line of the two consecutive studies and interval period
wash-in wash-out period (not shown) [3,6]. The baseline period is the cont
SOD. All centres continued SDD in the interval period (grey). The end of th
unit; SDD, selective digestive tract decontamination; SOD, selective orophaStatistical analysis
Prevalence for colistin and tobramycin resistance were
calculated separately per intervention period by dividing
the number of patients with one or more resistant iso-
lates per intervention period by the total number of pa-
tients included in the surveys of that intervention
period. Patients could participate in multiple sequential
surveys during one intervention period. The prevalence
of antibiotic resistance is given as percentage with 95%
confidence intervals (CI). Relative risks (RR) and 95% CI
were calculated to compare the prevalence of resistance
between the two study periods.
Results
The average duration of SDD/SOD use per ICU was
7.05 years (range 6.8 to 7.5 years), excluding the 6-month
standard care period of study period I. A timeline of the
two studies can be found in Figure 1. During study period
I, 1,007 respiratory and 1,093 rectal samples were obtained
from 1,189 patients in the five participating ICUs. During
study period II, 1,755 respiratory and 1,808 rectal samples
were obtained from 1,865 patients.
The prevalence for colistin resistance in rectal samples
ranged from 1.2% (during SOD) to 2.8% (during SDD) in
study period I, and were 1.7% and 1.1% during SDD and
SOD, respectively in study period II (Figure 2). In re-
spiratory tract samples, the prevalence for colistin resist-
ance ranged from 0.88% (standard care) to 2.1% (SDD)
in study period I and were 1.1% and 0.6% during SDD
and SOD in study period II (Figure 3). There were no
statistically significant differences between study periods
or between intervention periods, except for a significant
decrease in colistin resistance in rectal samples during
the SOD period of study period II compared to the
standard care period of study period I (RR 0.41 (0.17 to
0.98)) (Table 1).. (a) In both studies interventions were separated by a one month
rol period in which ICUs used standard care, not including SDD or
e intervention period marks the end of the study. ICU, intensive care
ryngeal decontamination.
Figure 2 Colistin resistance in rectal samples. Prevalence of gram-negative bacteria with intermediate susceptibility (I) or resistant (R) to colistin in
rectal samples obtained during study period 1 and 2 respectively.
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ples in study period I was lowest during SDD (6.6%), as
compared to standard care (RR 0.54 (0.34 to 0.87) and
SOD (RR 0.46 (0.29 to 0.72)) (Figure 4). In study period
II, the prevalence was 4.2% during SDD (RR 0.64 (0.40
to 1.04) as compared to SDD in study period I) and 8%
during SOD (RR 0.56 (0.39 to 0.78) as compared to SOD
in study period I) (Table 1). The prevalence for tobra-
mycin resistance in respiratory samples during SDD in
study period I was (6.7%), which was lower than during
standard care and SOD (RR 0.61 (0.38 to 1.00) and 0.71
(0.42 to 1.18), respectively). In study period II, the preva-
lence was 5.3% during SDD (RR 0.78 (0.49 to 1.25) as
compared to SDD in study period I) and 4.5% during
SOD (RR 0.48 (0.30 to 0.76) as compared to SOD in
study period I) (Table 1 and Figure 5).
As compared to the standard care period in study
period I, the average point prevalence of tobramycin re-
sistance in rectum samples had declined in study periodFigure 3 Colistin resistance in respiratory samples. Prevalence of gram
colistin in respiratory samples obtained during study period 1 and 2 respecII; from 12.1% in the standard care period of study
period I to 4.2% during SDD and 8% during SOD in rec-
tal swabs (RR 0.35 (0.23 to 0.53) and 0.66 (0.47 to 0.95),
respectively), and from 10.9% in the standard care period
of study period I to 5.3% during SDD (RR 0.48 (0.32 to
0.73) and 4.5% during SOD in respiratory tract samples
(RR 0.42 (0.27 to 0.64)) (Table 1).
The identified species and their counts in each study
period are available in Additional file 2.Discussion
In this longitudinal ecological study, spanning a period
of 7 years, we found no evidence of increasing resistance
to colistin in ICUs using SDD and SOD. Moreover, re-
sistance to tobramycin among gram-negative bacteria
was lower after several years of SDD and SOD.
These findings provide further evidence on the eco-
logical effects of SDD and SOD in settings with low levels-negative bacteria with intermediate susceptibility (I) or resistant (R) to
tively.
Table 1 Relative risk of colistin and tobramycin resistance
Relative risk (95% CI)
SDD study II SDD study II SOD study II SOD study II
vs. standard care vs. study I vs. standard care vs. study I
Colistin
Rectum 0.63 (0.29-1.38) 0.62 (0.29-1.33) 0.41 (0.17-0.98) 0.94 (0.30-2.97)
Respiratory tract 1.26 (0.35-4.57) 0.52 (0.21-1.31) 0.66 (0.16-2.73) 0.34 (0.10-1.18)
Tobramycin
Rectum 0.35 (0.23-0.53) 0.64 (0.40-1.04) 0.66 (0.47-0.95) 0.56 (0.39-0.78)
Respiratory tract 0.48 (0.32-0.73) 0.78 (0.49-1.25) 0.42 (0.27-0.64) 0.48 (0.30-0.76)
CI, confidence interval; SDD, selective digestive tract decontamination; SOD, selective oropharyngeal decontamination.
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during short-term use [3,6].
The current results support previous findings obtained
from two longitudinal studies in Germany and Spain
using clinical culture results and surveillance cultures,
respectively [7,8]. In a French retrospective study, span-
ning 6 years, carriage of antibiotic-resistant bacteria
based on clinical culture results was compared for indi-
vidual patients receiving or not receiving SDD, yielding
no changes in resistance among gram-negative bacteria
[9]. In 17 Dutch ICUs that continuously used SDD or
SOD during 4 years of follow-up, there was no increase
in resistance against colistin and tobramycin among
gram-negative bacteria, while resistance against third-
generation cephalosporins and ciprofloxacin decreased
during the follow-up period [10].
The current results are based on point prevalence sam-
ples obtained from all patients present in the ICU on a
predefined moment, also including patients not directly
exposed to SDD or SOD, thus reflecting the ICU ecology.
If SDD or SOD would directly cause antibiotic resistance
in exposed patients, inclusion of non-exposed patientsFigure 4 Tobramycin resistance in rectal samples. Prevalence of gram-n
tobramycin in rectal samples obtained during study period 1 and 2 respecwould dilute this effect, creating a bias towards null. How-
ever, in a previous analysis of patients receiving SDD or
SOD during study period I antibiotic resistance was lower
than during standard care [11].
Results of the second cluster-randomised cross-over
study, performed in 16 ICUs yielded a 7% and 4% monthly
increase in the prevalence of aminoglycoside-resistant
gram-negative bacteria in rectal samples during 12 months
of SDD and 12 months of SOD, respectively [6]. In
addition, SDD was associated with an increase in amino-
glycoside resistance genes in the non-culturable intestinal
flora in some patients [12]. These findings are in contrast
with the current findings, which might be related to differ-
ences in the duration of follow-up (7 years versus
24 months), study population (five ICUs versus 16 ICUs),
and detection methods (conventional microbiology versus
metagenomics approaches). Careful monitoring of amino-
glycoside resistance should, therefore, be performed dur-
ing SDD or SOD.
Clonal spread of colistin-resistant extended-spectrum
beta-lactamase (ESBL)-producing Klebsiella pneumonia
has been described after introduction of SDD during anegative bacteria with intermediate susceptibility (I) or resistant (R) to
tively.
Figure 5 Tobramycin resistance in respiratory samples. Prevalence of gram-negative bacteria with intermediate susceptibility (I) or resistant
(R) to tobramycin in respiratory samples obtained during study period 1 and 2 respectively.
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tion control measures [13]. That situation markedly dif-
fered from the non-outbreak study settings. In the
Netherlands, the prevalence of multidrug resistance
among both gram-negative and gram-positive bacteria in
general is low [6,10,11].
This study has some limitations. Adjustment for secu-
lar trends of antibiotic resistance was not possible, since
there was no data from ICUs that did not use SDD or
SOD. Yet, in an analysis of trends of resistance against
aminoglycosides and colistin among enterobacteriaceae
between 2008 and 2012 in 13 Dutch hospitals in which
no SDD or SOD was used a significant change could not
be demonstrated [10].
Furthermore, distributions of MIC values were lacking
in the current study.
Changes in case mix on the ICUs and implementation
of other interventions (that is infection control measures)
that influence the prevalence of antibiotic resistance could
have occurred during the interval between the two studies,
although based on reports of the participating hospitals
we have no indication that either of these took place.
Analysis of third-generation cephalosporin resistance
was not performed as different selective culture media
were used for screening in both study periods. Moreover,
polymyxin B (5 mg/l) and polymyxin E (4 mg/l) were
used for screening in study periods I and II, respectively,
but it is unlikely that this had consequences for our find-
ings, since there is complete cross-resistance between
colistin and polymyxin B [13].Conclusions
This study did not find an increase in the prevalence of
resistance against colistin and tobramycin among gram-
negative isolates during a mean of 7 years of SDD or
SOD use.The effect of SDD and SOD in settings with higher
levels of antibiotic resistance than the Netherlands re-
mains to be determined.
Key message
 The continued use of SDD or SOD for 7 years in a
setting with low levels of antibiotic resistance did
not lead to an increase in the (point) prevalence of
colistin and tobramycin resistance among gram-
negative bacteria.
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